Summer 2026

Oncology TR Scientist Intern

Posted on 11/1/2025

Deadline 11/3/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Ambler, PA, USA

Hybrid

Hybrid role; on-site 3 days/week, remote 2 days/week.

Category
Lab & Research (5)
, , , ,
Required Skills
Python
R
Requirements
  • Legally/permanently authorized to work in the US with no required sponsorships. Curricular Practical Training (CPT) requirements must be communicated at time of application
  • Must be currently enrolled in an accredited University or College program throughout the duration of the internship
  • Must not be graduating before, during, or after the start or end of the internship program
  • Undergraduate students with completion of at least four semesters at program start or graduate students are eligible
  • Minimum cumulative GPA of 3.0 which is reflective of all college coursework
  • Student in good standing, working towards the completion of an undergraduate or graduate degrees
  • Must have experience or pursuing a degreein biology,translational research/computational biology, cell/molecular biology, biochemistry, genetics, immunology/immuno-oncology,precision medicine and diagnostics or similar fields
  • Graduate students must be pursuing a master’sor a PhD degree
  • Self-motivatedfuture scientist leaderspassionate about drug development and clinical research
  • Proven leadership/participation with campus programs and/or service programs is desired
  • Detailed oriented with good organizational skills
  • Possess strong leadership skills to participate and contribute to internship program initiatives and events
  • Fluent in written and spoken English
  • Great interpersonal,verbal and written communication and presentation skills
  • Ability to lead peers, project teams and present to project and senior leadership teams
  • Enthusiastic, collaborative, able to build relationships and work within global matrixed and cross-functional teams
  • Ability to analyze data using standard coding-based analytical platforms (e.g., R, Python, etc.)
  • Ability to work on and balance multiple project deliverables
  • Working knowledge and/or experience using Slack, Microsoft suite of business applications/tools including but not limited to Excel, OneNote, Outlook, PowerPoint, Sharepoint, Teams, and Word, etc.
Responsibilities
  • Experimental design and execution
  • Participating in department and team meetings
  • Participating in cross-functional team meetings
  • Attend “Bench to Bedside” Lecture Series to gain knowledge of the drug development process and clinical research
  • Data collection and recording keeping
  • Hypothesis-driven data mining
  • Ability to quickly and quantitatively assess PD effect, and patient response to intervention to enable go/no go decisions in clinical trials, patient stratification for developing assets, and PD monitoring in in-vitro assays
  • Shadowing key functional roles for learning/development opportunities
  • Assisting with interpretation,reporting, and preparation of oral and written results of product research, in concert with senior clinical personnel
  • Work with a physician or clinical scientist to support ongoing or planned clinical studies
  • Work with a biomarker scientist or computational biologist to conduct research or support biomarker strategy development through assay development, analysis or logistical support to progress a clinical study
  • Work on projects related to target validation and patient stratification using multiomics datasets (e.g. genetics, transcriptomics, proteomics)
  • Review of literature on disease-specific biologyand related new technologies
  • Assist with interpretation, reporting, and preparation of oral and written results of the analyses performed, in discussion with mentor and other colleagues
  • Leadership opportunities on specific internship programs activities and/or group projects
  • Abstract/ poster preparation and presentation at organization-wide annual research symposium
  • Other projects as assigned
Desired Qualifications
  • Proven leadership/participation with campus programs and/or service programs is desired

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI and RYBREVANT are driving near-term oncology growth.
  • IMAAVY and CAPLYTA expand J&J into rare immunology and neuropsychiatry.
  • The Firefly Bio acquisition adds a pan-KRAS oncology platform.

What critics are saying

  • STELARA biosimilar erosion is already cutting a major immunology franchise.
  • Firefly Bio's KRAS platform remains early and can fail clinically.
  • AI surgery and Shockwave launches face adoption, reimbursement, and execution risk.

What makes Johnson & Johnson unique

  • J&J focuses on Innovative Medicine and MedTech after spinning off Kenvue in 2023.
  • Its portfolio spans oncology, immunology, neuroscience, cardiovascular, and surgical robotics.
  • The company combines internal R&D with acquisitions like Abiomed, Shockwave, and Ambrx.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE